Journal of Clinical Oncology, Vol 4, 544-551, Copyright © 1986 by American Society of Clinical Oncology

ARTICLES

Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon

FX Real, HF Oettgen and SE Krown

The efficacy of recombinant leukocyte A interferon (rIFN-alpha A [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome was evaluated in sequential trials using high doses (36 X 10(6) units) and low doses (3 X 10(6) units) of interferon. A major response was seen in 38% of patients treated at the high dose, with a median response duration of 18 months. At the low dose, the major response rate was 3%; dose escalation to 36 X 10(6) units resulted in an additional major response rate of 17% in low-dose nonresponders, with a median response duration of 10 months. Four of 11 patients who achieved a complete response remain free of disease, whereas all partial responders have shown disease progression. Unacceptable toxicity occurred in 27% of patients initially treated at the high dose and only in 10% of those who had progressive dose escalation up to 36 X 10(6) units. Prior opportunistic infections correlated negatively with therapeutic response, whereas large tumor burden and gastrointestinal involvement did not. Responding patients showed a significantly longer survival and a lower incidence of subsequent opportunistic infections than nonresponders. However, from our study we cannot determine whether rIFN- alpha A has an effect on the natural history of Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. N. Lara Jr., D. I. Quinn, K. Margolin, F. J. Meyers, J. Longmate, P. Frankel, P. C. Mack, C. Turrell, P. Valk, J. Rao, et al. SU5416 Plus Interferon {alpha} in Advanced Renal Cell Carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition Clin. Cancer Res., October 15, 2003; 9(13): 4772 - 4781. [Abstract] [Full Text] [PDF]

				S. F. Huang, S.-J. Kim, A. T. Lee, T. Karashima, C. Bucana, D. Kedar, P. Sweeney, B. Mian, D. Fan, D. Shepherd, et al. Inhibition of Growth and Metastasis of Orthotopic Human Prostate Cancer in Athymic Mice by Combination Therapy with Pegylated Interferon-{alpha}-2b and Docetaxel Cancer Res., October 15, 2002; 62(20): 5720 - 5726. [Abstract] [Full Text] [PDF]

				J. W. Slaton, T. Karashima, P. Perrotte, K. Inoue, S. J. Kim, J. Izawa, D. Kedar, D. J. McConkey, R. Millikan, P. Sweeney, et al. Treatment with Low-Dose Interferon-{alpha} Restores the Balance between Matrix Metalloproteinase-9 and E-Cadherin Expression in Human Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., September 1, 2001; 7(9): 2840 - 2853. [Abstract] [Full Text] [PDF]

				E. Jonasch and F. G. Haluska Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities Oncologist, February 1, 2001; 6(1): 34 - 55. [Abstract] [Full Text]

				I. J. Fidler Regulation of Neoplastic Angiogenesis J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 10 - 14. [Abstract] [Full Text] [PDF]

				Y.-K. Hong, D.-S. Chung, Y.-A. Joe, Y.-J. Yang, K.-M. Kim, Y.-S. Park, W. K. A. Yung, and J.-K. Kang Efficient Inhibition of In Vivo Human Malignant Glioma Growth and Angiogenesis by Interferon-{beta} Treatment at Early Stage of Tumor Development Clin. Cancer Res., August 1, 2000; 6(8): 3354 - 3360. [Abstract] [Full Text]

				J. W. Slaton, P. Perrotte, K. Inoue, C. P. N. Dinney, and I. J. Fidler Interferon-{{alpha}}-mediated Down-Regulation of Angiogenesis-related Genes and Therapy of Bladder Cancer Are Dependent on Optimization of Biological Dose and Schedule Clin. Cancer Res., October 1, 1999; 5(10): 2726 - 2734. [Abstract] [Full Text] [PDF]

				P. Monini, F. Carlini, M. Sturzl, P. Rimessi, F. Superti, M. Franco, G. Melucci-Vigo, A. Cafaro, D. Goletti, C. Sgadari, et al. Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells J. Virol., May 1, 1999; 73(5): 4029 - 4041. [Abstract] [Full Text] [PDF]

				D. Lev-Chelouche, S. Abu-Abeid, O. Merimsky, J. Isakov, Y. Kollander, I. Meller, J. M. Klausner, and M. Gutman Isolated Limb Perfusion With High-Dose Tumor Necrosis Factor {alpha} and Melphalan for Kaposi Sarcoma Arch Surg, February 1, 1999; 134(2): 177 - 180. [Abstract] [Full Text] [PDF]

				C. S. C. da Cunha, C. Lebbe, M. Rybojad, F. Agbalika, F. Ferchal, C. Rabian, M. D. Vignon-Pennamen, F. Calvo, and P. Morel Long-term Follow-up of Non-HIV Kaposi's Sarcoma Treated With Low-Dose Recombinant Interferon Alfa-2b Arch Dermatol, March 1, 1996; 132(3): 285 - 290. [Abstract] [PDF]

				E. Tur, S. Brenner, and R. Michalevicz Low Dose Recombinant Interferon Alfa Treatment for Classic Kaposi's Sarcoma Arch Dermatol, October 1, 1993; 129(10): 1297 - 1300. [Abstract] [PDF]

				S. E. Krown, J. W.M. Gold, D. Niedzwiecki, D. Bundow, N. Flomenberg, B. Gansbacher, and B. J. Brew Interferon-{alpha} with Zidovudine: Safety, Tolerance, and Clinical and Virologic Effects in Patients with Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS) Ann Intern Med, June 1, 1990; 112(11): 812 - 821. [Abstract] [PDF]

				S. A. Miles, H. Wang, E. Cortes, J. Carden, S. Marcus, and R. T. Mitsuyasu Beta-Interferon Therapy in Patients with Poor-Prognosis Kaposi Sarcoma Related to the Acquired Immunodeficiency Syndrome (AIDS) A Phase II Trial with Preliminary Evidence of Antiviral Activity and Low Incidence of Opportunistic Infections Ann Intern Med, April 15, 1990; 112(8): 582 - 589. [Abstract] [PDF]

				J. E. Groopman and D. T. Scadden Interferon Therapy for Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS) Ann Intern Med, March 1, 1989; 110(5): 335 - 337. [Abstract] [PDF]